Le Lézard
Classified in: Health, Science and technology
Subject: Funding

XLerateHealth Receives NIH Funding to Continue Development of Healthcare Innovation in Under-Resourced States


XLerateHealth (XLH) is pleased to announce that it was awarded Phase II funding of $1.48M, plus an Administrative Supplement of $250,000, from the National Institutes of Health (NIH) to continue building the XLerator Network, one of four Institutional Development Award (IDeA) State region "hubs" supported by the Small Business Technology Transfer (STTR) program. The STTR program funds research and development partnerships between small businesses and academic institutions.

The grant, managed by the National Institutes of General Medical Sciences (NIGMS), is a part of funding expected to total more than $3.6M for XLH and its partners through 2021. XLH's partners on this grant include 24 Academic Institutions with the University of Kentucky serving as the Academic Lead.

The Administrative Supplement of $250,000 will fund creation of the "Ideas to Products" (I2P) program, which will support faculty, students and researchers in the XLerator Network with competitive funding that will help them ready their technologies for commercialization.

Established by Congressional mandate in 1993, the IDeA program's goal is to broaden the geographic distribution of NIH funding and to help accelerate early-stage biomedical technology from the laboratory to market, with an emphasis on supporting geographically underserved areas in healthcare. The XLerator Network supports the Southeast IDeA State region, which includes Kentucky, Arkansas, Mississippi, Louisiana, South Carolina, West Virginia, and Puerto Rico.

"We are honored and grateful to receive a continuation of funds from NIGMS to support our efforts in developing academic innovation within areas of the country that are historically underserved," says Jackie Willmot, CEO & Co-founder of XLH. "These resources will have a significant impact on our ability to realize the potential of promising healthcare innovation across the Southeast."

The continuation of the grant secures a second year of funding for XLH and its partners to build on foundational assessment and planning work completed in year one. Phase II funds will be allocated to building the architecture and functionality of various tools, curricula and resources, including an assessment tool that will provide a personalized roadmap for researchers, faculty and students to learn how to take their innovations from lab to market.

In support of this continued work, XLH also launched a Scientific Advisory Committee and External Advisory Committee consisting of leaders across the healthcare ecosystem nationally, from pharmaceutical and medical device companies to investors, academia, and serial entrepreneurs. The committees will provide hands-on support for companies developing out of affiliated Southeastern IDeA universities.

About XLerateHealth:

Founded in 2013, XLerateHealth (XLH) exists to cultivate and grow impactful healthcare innovation in the Midwest, Southeast and other areas of the country where great innovation often goes unrecognized and underfunded. XLH supports the development of healthcare innovation through the XLH Accelerator, an early-stage healthcare accelerator that helps start-ups commercialize their business and attract funding, and the XLerator Network, a partnership with 24 academic institutions to support R&D development in the NIH's Southeast Institutional Development Award (IDeA) states.

XLH has evolved to become one of longest standing healthcare accelerator programs in the US. In January of 2019, the accelerator program expanded to Flint, Michigan.

Find out more about XLH by visiting www.xleratehealth.com. XLH is on Facebook, LinkedIn and Twitter @XlerateHealth.


These press releases may also interest you

at 09:30
Emerald Health Therapeutics, Inc. ("Emerald") , has entered into a binding term sheet with a single Canadian institutional accredited investor (the "Investor") under which the Investor has agreed, subject to certain customary conditions, to purchase...

at 09:29
Perrigo Company plc , today announced that CEO and President, Murray S. Kessler and CFO, Ray Silcock, will present at the Morgan Stanley Global Consumer & Retail Conference at 10:00 AM EST on Wednesday, December 4, 2019.  Interested parties can...

at 09:25
Applied DNA Sciences, Inc. ("Applied DNA" or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions and nucleic acid-based biotherapeutic research, today announced the...

at 09:17
High Falls Hemp NY announces the launch of their newest product, the CBD Starter Collection. The assortment consists of three ways to take CBD in trial sizes, packaged in an attractive box that makes the ideal holiday gift ? the gift of wellness. CBD...

at 09:17
First Responsetm, the pregnancy and ovulation test kit brand dedicated to assisting couples on their pregnancy journey, is proud to announce its partnership with Habitat for Humanity as they expand their 'Baby's First Home' campaign. This...

at 09:15
Neoleukin Therapeutics, Inc. "Neoleukin" , a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced a corporate update and financial results for the third quarter ending...



News published on 21 october 2019 at 08:05 and distributed by: